利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.022 秒)

    ANALGESIC
    3.
    发明申请
    ANALGESIC 审中-公开

    公开(公告)号：US20130296426A1

    公开(公告)日：2013-11-07

    申请号：US13979723

    申请日：2012-01-30

    申请人： Munekazu Iinuma ,  Shoei Furukawa ,  Mitsuru Naiki ,  Tomoyuki Okada ,  Tomonori Matsumoto ,  Kazuyoshi Sawada

    发明人： Munekazu Iinuma ,  Shoei Furukawa ,  Mitsuru Naiki ,  Tomoyuki Okada ,  Tomonori Matsumoto ,  Kazuyoshi Sawada

    IPC分类号： A61K31/23 ,  A61K31/231

    CPC分类号： A61K31/23 ,  A61K31/231

    摘要： An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.

    摘要翻译： 本发明的目的是提供一种有效预防或治疗各种疼痛疾病的止​​痛剂。 本发明提供一种含有C10脂肪酸的酯作为活性成分的止痛剂。 含有该化合物作为活性成分的本发明的止痛剂作为各种疼痛疾病例如由骨关节炎（例如膝关节骨性关节炎和髋关节骨性关节炎）引起的疼痛或脱髓鞘性疾病如多发性硬化症的预防或治疗剂是非常有用的 或吉兰 - 巴雷综合征。

    Anti-edema agent
    5.
    发明授权
    Anti-edema agent 失效
    抗水肿剂

    公开(公告)号：US06238665B1

    公开(公告)日：2001-05-29

    申请号：US09434495

    申请日：1999-11-05

    申请人： Mitsuru Naiki

    发明人： Mitsuru Naiki

    IPC分类号： A61K39395

    CPC分类号： A61K31/415 ,  A61K39/395 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising a pharmaceutically effective amount of histamine-added immunoglobulin substantially suppresses edema formation and an increase of vascular permeability of the blood-brain barrier. The histamine-added immunoglobulin may be administered with a high degree of safety and a low incidence of side effects. The histamine-added immunoglobulin and pharmaceutical compositions containing it may be used for treatment and prevention of edema, edema formation, and an increase of vascular permeability of the blood-brain barrier.

    摘要翻译： 包含药学有效量的组胺加入的免疫球蛋白的药物组合物基本上抑制血脑屏障的水肿形成和血管通透性的增加。 可以以高度的安全性和低的副作用发生施用组胺加免疫球蛋白。 含有组胺的免疫球蛋白和含有它的药物组合物可用于治疗和预防血脑屏障的水肿，水肿形成和血管通透性的增加。

    Method for study, determination or evaluation by gene expression analysis
    6.
    发明申请
    Method for study, determination or evaluation by gene expression analysis 审中-公开
    通过基因表达分析进行研究，测定或评估的方法

    公开(公告)号：US20100048408A1

    公开(公告)日：2010-02-25

    申请号：US12310623

    申请日：2007-09-05

    申请人： Mitsuru Naiki ,  Tomoyuki Okada

    发明人： Mitsuru Naiki ,  Tomoyuki Okada

    IPC分类号： C40B30/00 ,  C12Q1/68 ,  A61K35/12 ,  A01K67/00

    CPC分类号： C12Q1/6883 ,  C12Q2600/158 ,  G01N33/50

    摘要： There is provided a method for study, determination or evaluation of a disease condition due to SART stressing or a pharmacological activity, for example an analgesic activity, an autonomic imbalance-ameliorating activity or an anti-stress activity, of a test substance at the gene level. It is a method for study, determination or evaluation of a pharmacological activity of a test substance, especially an analgesic activity, an autonomic imbalance-ameliorating activity, or an anti-stress activity at the gene level by comprehensively analyzing the change in gene expression in a neural tissue after administration of a test substance in a SART-stressed animal. The method enables exploration of the substance that is effective against painful diseases, stress-related diseases, autonomic-imbalance or the like, determination and evaluation of efficacy of the substance, or analysis of a target gene of the substance

    摘要翻译： 提供了一种用于研究，测定或评估由于SART应激或药理学活性引起的疾病状况的方法，例如在基因上测试物质的止痛活性，自主失调 - 改善活性或抗应激​​活性 水平。 它是通过综合分析基因表达变化来研究，测定或评估测试物质的药理活性，特别是镇痛活性，自主神经不平衡改善活性或基因水平的抗应激活性的方法 在SART受压动物中施用测试物质后的神经组织。 该方法能够探索对抗痛性疾病，应激相关疾病，自主神经不平衡等有效的物质，物质的功效的测定和评估，或物质的靶基因的分析

    Therapeutic agent for intractable vasculitis
    8.
    发明授权
    Therapeutic agent for intractable vasculitis 失效
    难治性血管炎治疗剂

    公开(公告)号：US06251929B1

    公开(公告)日：2001-06-26

    申请号：US09434494

    申请日：1999-11-05

    申请人： Mitsuru Naiki ,  Takumi Numazawa ,  Tomoyuki Okada ,  Kazuharu Ienaga ,  Kazuyoshi Sawada

    发明人： Mitsuru Naiki ,  Takumi Numazawa ,  Tomoyuki Okada ,  Kazuharu Ienaga ,  Kazuyoshi Sawada

    IPC分类号： A64K31415

    CPC分类号： A61K31/4166

    摘要： A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1, and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.

    摘要翻译： 用于顽固性血管炎的恶性类风湿性关节炎的高度安全的治疗剂含有式（I）表示的乙内酰脲衍生物或其药学上可接受的盐作为有效成分：其中R1和R2可以相同或不同 表示氢，烷基或环烷基; X和Y各自可以相同或不同，表示氢，羟基，烷基或烷氧基，或X和Y一起表示氧代基。 乙内酰脲衍生物显着抑制模型动物（MRL / lpr）中天然发育的关节炎和动脉炎（皮肤溃疡和耳廓梗塞坏死）的产生，并进一步显着延长MRL / lpr小鼠的存活率。 因此，具有低毒性和少量副作用的乙内酰脲衍生物作为难治性血管炎如恶性类风湿性关节炎的高度安全的治疗剂是非常有用的。

    Optically active (R)-hydantoin derivative
    9.
    发明申请
    Optically active (R)-hydantoin derivative 审中-公开
    光活性（R） - 乙内酰脲衍生物

    公开(公告)号：US20060241162A1

    公开(公告)日：2006-10-26

    申请号：US11110111

    申请日：2005-04-20

    申请人： Kaoru Okamoto ,  Akira Ishii ,  Nobuhisa Okukado ,  Hirohide Matsuura ,  Mitsuru Naiki ,  Kazuyoshi Sawada

    发明人： Kaoru Okamoto ,  Akira Ishii ,  Nobuhisa Okukado ,  Hirohide Matsuura ,  Mitsuru Naiki ,  Kazuyoshi Sawada

    IPC分类号： A61K31/4166 ,  C07D233/04

    CPC分类号： C07D233/66

    摘要： (R)-(+)-5-hydroxy-1-methylhydantoin is an optically active substance having an excellent suppressive action of the progression of renal failure. At an administration to a model animal of renal failure, (R)-(+)-5-hydroxy-1-methylhydantoin significantly suppresses an increase of creatinine in blood as compared with the S-form and the racemate, and shows an excellent suppressive action to the progression of renal failure by improving creatinine clearance. Thus, (R)-(+)-5-hydroxy-1-methylhydantoin is useful as a highly-active agent for renal failure.

    摘要翻译： （R） - （+） - 5-羟基-1-甲基乙内酰脲是具有优异的肾衰竭进展的抑制作用的光学活性物质。 （R） - （+） - 5-羟基-1-甲基乙内酰脲在给予肾功能衰竭模型动物时，与S型和外消旋体相比显着抑制血液中肌酸酐的增加，显示出优异的抑制作用 通过改善肌酐清除率来促进肾衰竭的进展。 因此，（R） - （+） - 5-羟基-1-甲基乙内酰脲可用作肾功能衰竭的高活性剂。

    Drug for kidney failure containing oxaluric acid derivative
    10.
    发明申请
    Drug for kidney failure containing oxaluric acid derivative 审中-公开
    含有草酸衍生物的肾衰竭药物

    公开(公告)号：US20050245577A1

    公开(公告)日：2005-11-03

    申请号：US10526527

    申请日：2003-09-10

    申请人： Mitsuru Naiki ,  Takumi Numazawa

    发明人： Mitsuru Naiki ,  Takumi Numazawa

    IPC分类号： A61K31/22 ,  A61P13/12 ,  A61K31/445 ,  A61K31/195 ,  A61K31/401

    CPC分类号： A61K31/22

    摘要： The effective ingredient of the agent for renal failure of the present invention is an oxaluric acid derivative having an excellent suppressive effect of the progression of renal failure. The oxaluric acid derivatives of the present invention have an excellent suppressive effect of the progression of renal failure to inhibit significantly the increase of creatinine level in blood accompanied by the progression of renal failure. The compounds of the present invention have highly safety with little side effects, so that they are very useful as an agent for renal failure which is required to be administered for long term.

    摘要翻译： 本发明的肾功能衰竭药物的有效成分是对肾衰竭进展具有优异抑制作用的草酸衍生物。 本发明的草酸衍生物对肾功能衰竭的进展具有优异的抑制作用，从而显着地抑制伴随肾衰竭进展的血液中肌酐水平的升高。 本发明的化合物具有高度安全性，副作用小，因此它们作为需要长期施用的肾功能衰竭药物是非常有用的。